2X Blend CJC-1295 Without DAC (5mg) / Ipamorelin (5mg)

Description

This 2X Blend combines CJC-1295 Without DAC (Mod-GRF 1-29, 5mg) and Ipamorelin (5mg) — two mechanistically complementary GH secretagogues that act through separate but convergent pathways to produce synergistic GH release. CJC-1295 Without DAC activates the GHRH receptor on somatotrophs; Ipamorelin activates the ghrelin receptor (GHSR-1a). Their simultaneous administration is the standard combination protocol in GH axis research because the two pathways produce additive, not merely additive, GH output.

Component Roles

• CJC-1295 Without DAC (5mg): Modified GHRH(1-29) with four stabilizing amino acid substitutions. Produces pulsatile GH release through GHRH receptor agonism, closely mimicking the natural somatotroph secretory pattern.
• Ipamorelin (5mg): Selective pentapeptide GHSR-1a agonist (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that releases GH via the ghrelin pathway without stimulating cortisol, ACTH, or prolactin at research concentrations.

Why Researchers Use This Combination

GHRH primes somatotrophs to respond to GH secretagogues by increasing GHSR expression; Ipamorelin then triggers release through GHSR-1a. This dual-pathway activation produces GH pulses significantly larger than either compound alone — the physiological basis for their use in synergistic GH axis research. Ipamorelin’s selectivity ensures that the combined response reflects pure GH pathway activation without HPA axis confounding.

Common Research Applications

• Synergistic GH secretion and GHRH/GHSR dual-pathway studies
• Somatotroph sensitization and response characterization
• GH/IGF-1 axis investigation via complementary pathways
• GH pulse amplitude comparison studies

For Research Use Only. Not for human or veterinary use.